Maze TherapeuticsMAZE +5.18%14 Current Ratio is 17.88 as of Mar. 2026, which is 53% above its 10-year median of 11.70. GuruFocus rates MAZE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Maze Therapeutics ranks better than 90.02% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Maze Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 17.88.
Maze Therapeutics has a current ratio of 17.88. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Maze Therapeutics's Current Ratio or its related term are showing as below:
MAZE'
s Current Ratio Range Over the Past 10 Years
Min: 2.09 Med: 11.7 Max: 17.88
Current: 17.88
During the past 4 years, Maze Therapeutics's highest Current Ratio was 17.88. The lowest was 2.09. And the median was 11.70.
MAZE's Current Ratio is ranked better than 90.02% of 1413
companies
in the Biotechnology industry
Industry Median: 3.89
vs MAZE: 17.88
Maze Therapeutics (NAS:MAZE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Maze Therapeutics Current Ratio Related Terms
Maze Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Maze Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maze Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maze Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Maze Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maze Therapeutics (MAZE) has a Current Ratio of 17.88 as of Mar. 2026. This is 53% above median its historical median of 11.70. Over the past decade, Maze Therapeutics' Current Ratio has ranged from 2.09 to 17.88. According to the industry distribution chart, Maze Therapeutics ranks #141 out of 1413 companies in the Biotechnology industry, placing it in the top 10%.
Is Maze Therapeutics' Current Ratio too high?
Maze Therapeutics' current Current Ratio of 17.88 is 53% above median its 10-year median of 11.70. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 17.88. The Biotechnology industry median Current Ratio is 3.89. Maze Therapeutics' value of 17.88 is 359.6% above this industry median. Based on the distribution chart, Maze Therapeutics ranks #141 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Maze Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Current Ratio compare to FTRE and ARDX?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #141 out of 1413 companies for Current Ratio. This places Maze Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Maze Therapeutics' value of 17.88 is 359.6% above this benchmark. Historically, Maze Therapeutics' own Current Ratio has ranged from 2.09 to 17.88 over the past decade. While the company's 10-year median is 11.70 vs. the industry median of 3.89, Maze Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maze Therapeutics's current Current Ratio of 17.88 is 359.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current Current Ratio is 17.88, which is 53% above median its own 10-year median of 11.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Current Ratio of 17.88. The current Current Ratio is 17.88, which is 53% above median its 10-year median of 11.70 and 359.6% above the Biotechnology industry median of 3.89. Maze Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Current Ratio is 17.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
14GF Score
Get the complete analysis for MAZE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAZE has been successfully added to your 
